Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

1. Diagnosis and management of epilepsy in adults

Diagnosis and management of epilepsy in adults SIGN 143 • Diagnosis and management of epilepsy in adults A national clinical guideline Evidence May 2015 · Revised 2018KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias (...) in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Diagnosis and management of epilepsy in adults A national clinical guideline Revised 2018Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published

2018 SIGN

2. Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high

Cohort study: Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate of epilepsy in people with autism and the rate of autism in people with epilepsy are high Article Text Prognosis Cohort study Rate of epilepsy in people with autism and the rate

2016 Evidence-Based Medicine

3. Ketogenic diet and other dietary treatments for epilepsy. (PubMed)

Ketogenic diet and other dietary treatments for epilepsy. The ketogenic diet (KD), being high in fat and low in carbohydrates, has been suggested to reduce seizure frequency. It is currently used mainly for children who continue to have seizures despite treatment with antiepileptic drugs. Recently, there has been interest in less restrictive KDs including the modified Atkins diet (MAD) and the use of these diets has extended into adult practice.To review the evidence for efficacy (...) and tolerability from randomised controlled trials regarding the effects of KD and similar diets.We searched the Cochrane Epilepsy Group's Specialized Register (30 March 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 30 March 2015), MEDLINE (Ovid, 30 March 2015), ClinicalTrials.gov (30 March 2015) and the WHO International Clinical Trials Registry Platform (ICTRP, 30 March 2015). We imposed no language restrictions. We checked

Full Text available with Trip Pro

2016 Cochrane

4. Cannabinoids for refractory epilepsy treatment

Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Soto N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Cannabinoids for refractory epilepsy treatment. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 499. 2016 Authors' conclusions There is scarce and low quality evidence on cannabinoids (specifically cannabidiol) potential in reducing the frequency of seizures in patients with refractory epilepsy. The Clinical Practice Guidelines and health sponsors consulted do

2016 Health Technology Assessment (HTA) Database.

5. Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase

Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Seizures may be reduced in some severe drug-resistant epilepsies by a cannabis derivative Discover Portal Discover Portal Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase Published on 26 June 2018 doi: In people with some types of severe, drug-resistant epilepsy, adding cannabidiol to their treatment may reduce seizure (...) frequency and improve quality of life compared with a placebo. The likelihood of being free from seizures for more than a year was still low, about 8%. However, an additional 12% of people had serious adverse effects with cannabidiol. These findings come from a systematic review, which included six trials in 555 patients. Most were children and adolescents with rare forms of epilepsy, and findings may not apply to other forms of the condition. The included trials were poorly reported and show some bias

2019 NIHR Dissemination Centre

6. Epilepsies: diagnosis and management

Epilepsies: diagnosis and management Epilepsies: diagnosis and management Epilepsies: diagnosis and management Clinical guideline Published: 11 January 2012 nice.org.uk/guidance/cg137 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Epilepsies: diagnosis and management (CG137) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 98Contents Contents Overview 8 Who is it for? 8 Introduction 9 Key

2012 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Epilepsy in Pregnancy

Epilepsy in Pregnancy Epilepsy in Pregnancy Green-top Guideline No. 68 June 2016 Endorsed by:Epilepsy in Pregnancy This is the first edition of this guideline, produced by the Royal College of Obstetricians and Gynaecologists (RCOG) and endorsed by the following organisations: Association of British Neurologists, Epilepsy Action, Royal College of General Practitioners, Royal College of Midwives and the Royal College of Physicians. Executive summary of recommendations Diagnosis of epilepsy What (...) aspects of diagnosis are specific to pregnancy and the puerperium, including the definition of seizures for the obstetrician? The diagnosis of epilepsy and epileptiform seizures should be made by a medical practitioner with expertise in epilepsy, usually a neurologist. Women with a history of epilepsy who are not considered to have a high risk of unprovoked seizures can be managed as low-risk women in pregnancy. What is the importance of classifying seizure type and epilepsy syndrome? Women

2016 Royal College of Obstetricians and Gynaecologists

8. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs (...) % (95% CI 3.8% to 14.5%) were seizure-free. Twelve observational studies reported improved QoL (55.8%, 95% CI 40.5 to 70.6); 50.6% (95% CI 31.7 to 69.4) AEs and 2.2% (95% CI 0 to 7.9) SAEs. Pharmaceutical-grade CBD as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency. Existing RCT evidence is mostly in paediatric samples with rare and severe epilepsy syndromes; RCTs examining other syndromes and cannabinoids are needed.CRD42017055412.© Article author(s

Full Text available with Trip Pro

2018 EvidenceUpdates

9. Treatment of epilepsy for people with Alzheimer's disease. (PubMed)

Treatment of epilepsy for people with Alzheimer's disease. Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of the treatment. This review aims to review those different modalities.To assess the efficacy (...) and tolerability of the treatment of epilepsy for people with Alzheimer's disease (AD) (including sporadic AD and dominantly inherited AD).We searched the Cochrane Epilepsy Group Specialized Register (1 February 2016), the Cochrane Central Register of Controlled Trials (1 February 2016), MEDLINE (Ovid, 1 February 2016) and ClinicalTrials.gov (1 February 2016). In an effort to identify further published, unpublished and ongoing trials, we searched ongoing trials' registers, reference lists and relevant

Full Text available with Trip Pro

2016 Cochrane

10. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy AAN.com ©2018 American Academy of Neurology AAN and AES Summary of Practice Guideline for Clinicians Practice Guideline Update: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy This is a summary of the American Academy of Neurology (AAN) and American Epilepsy Society (AES) practice guideline, “Practice guideline update: Efficacy (...) and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy,” which was published online ahead of print in Neurology ® on June 13, 2018. It will appear in the July 10, 2018, print issue. Please refer to the full guideline at AAN.com/guidelines for more information, including descriptions of the processes for classifying evidence, deriving conclusions, and making recommendations. For adult patients with treatment-resistant (TR) focal epilepsy, are these antiepileptic drugs (AEDs

2018 American Academy of Neurology

11. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy

Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy AAN.com ©2018 American Academy of Neurology AAN and AES Summary of Practice Guideline for Clinicians Practice Guideline Update: Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-onset Epilepsy This is a summary of the American Academy of Neurology (AAN) and American Epilepsy Society (AES) practice guideline, “Practice guideline update (...) : Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy,” which was published online ahead of print in Neurology ® on June 13, 2018. It will appear in the July 10, 2018, print issue. Please refer to the full guideline at AAN.com/guidelines for more information, including full descriptions of the processes for classifying evidence, deriving conclusions, and making recommendations. For adults and children with newly diagnosed epilepsy, are the following drugs effective

2018 American Academy of Neurology

12. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability

Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) This site uses cookies: Search Search Become a psychiatrist Choose psychiatry Medical students Foundation doctors Help us promote psychiatry Training Curricula and guidance Your training Exams Neuroscience in training International Medical Graduates Members Supporting you Submitting your CPD Membership Your (...) drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) This report addresses the extremely important area of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social isolation. An individual who experiences both these problems faces huge challenges. This report aims

2018 Royal College of Psychiatrists

13. Management of epilepsy in adults with intellectual disability

Management of epilepsy in adults with intellectual disability Management of epilepsy in adults with intellectual disability (CR203 May 2017) This site uses cookies: Search Search Become a psychiatrist Choose psychiatry Medical students Foundation doctors Help us promote psychiatry Training Curricula and guidance Your training Exams Neuroscience in training International Medical Graduates Members Supporting you Submitting your CPD Membership Your Faculties Devolved Nations English Divisions (...) International members Special Interest Groups Your monthly eNewsletter Specialty doctors President's lectures Events Conferences and training events In house training International Congress Improving care CCQI Campaigning for better mental health policy Planning the psychiatric workforce National Collaborating Centre for Mental Health Working sustainably Mental health Problems and disorders Support, care and treatment Translations Management of epilepsy in adults with intellectual disability (CR203 May 2017

2018 Royal College of Psychiatrists

14. Cannabidiol (CBD) and Pediatric Epilepsy

Cannabidiol (CBD) and Pediatric Epilepsy Cannabidiol (CBD) and Pediatric Epilepsy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cannabidiol (CBD) and Pediatric Epilepsy The safety and scientific validity (...) medical marijuana has had a significant impact on the pediatric population of Colorado. There have been many reported different effects and properties of each of the over 60 known cannabinoids found in marijuana. The main exposures in pediatrics have involved the use of Cannabidiol (CBD) high- and Tetrahydrocannibinol (THC) low-content hash oil in children with epilepsy. The reported benefit of this oil is to have the anticonvulsant properties of CBD without the psychoactive components of THC. Human

2015 Clinical Trials

15. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) of neuropathic pain, epilepsy and generalised anxiety disorder (GAD) The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC). The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Lyrica instead of non-clinical and clinical unless justified otherwise. Information on paediatric requirements Not applicable Information relating to orphan market exclusivity

2017 European Medicines Agency - EPARs

16. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. (PubMed)

Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs. In this review, we focus on interventions designed and tested in randomised controlled trials and quasi-randomised controlled trials to assist people with adherence to antiepileptic medication. This is an updated version of the original Cochrane review published in the Cochrane Library (...) , Issue 1, 2010.To determine the effectiveness of interventions aimed at improving adherence to antiepileptic medication in adults and children with epilepsy.For the latest update, on 4 February 2016 we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 4 February 2016), CINAHL Plus (EBSCOhost 1937 to 4 February 2016), PsycINFO (EBSCOhost 1887 to 4 February

Full Text available with Trip Pro

2017 Cochrane

17. Ketogenic diets for drug-resistant epilepsy. (PubMed)

Ketogenic diets for drug-resistant epilepsy. Ketogenic diets (KDs), being high in fat and low in carbohydrates, have been suggested to reduce seizure frequency in people with epilepsy. At present, such diets are mainly recommended for children who continue to have seizures despite treatment with antiepileptic drugs (AEDs) (drug-resistant epilepsy). Recently, there has been interest in less restrictive KDs, including the modified Atkins diet (MAD), and the use of these diets has extended (...) into adult practice. This is an update of a review first published in 2003 and last updated in 2016.To assess the effects of KDs for drug-resistant epilepsy by reviewing the evidence from randomised controlled trials.For the latest update we searched the Cochrane Epilepsy Group's Specialized Register (11 April 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 11 April 2017), MEDLINE (Ovid, 11 April 2017), ClinicalTrials.gov (11 April

2018 Cochrane

18. Seizures and Epilepsy

Seizures and Epilepsy Date of origin: 1996 Last review date: 2014 ACR Appropriateness Criteria ® 1 Seizures andEpilepsy American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Seizures and Epilepsy Variant 1: Medically refractory epilepsy. Surgical candidate or surgical planning. Radiologic Procedure Rating Comments RRL* MRI head without IV contrast 8 O MRI head without and with IV contrast 8 O FDG-PET/CT head 7 This procedure may be helpful in preoperative planning (...) *Relative Radiation LevelACR Appropriateness Criteria ® 2 Seizures and Epilepsy Clinical Condition: Seizures and Epilepsy Variant 3: New-onset seizure. Unrelated to trauma. Age 18–40. Radiologic Procedure Rating Comments RRL* MRI head without IV contrast 8 In the acute or emergency setting, CT may be the imaging study of choice. O MRI head without and with IV contrast 7 In the acute or emergency setting, CT may be the imaging study of choice. O CT head without IV contrast 7 In the acute or emergency

2014 American College of Radiology

20. Epilepsy surgery: invasive monitoring for epilepsy surgery, nursing management

Epilepsy surgery: invasive monitoring for epilepsy surgery, nursing management Invasive monitoring (IM) and Stereo-electroencephalography (SEEG) for epilepsy surgery: nursing management | Great Ormond Street Hospital Google Tag Manager Navigation Search Search You are here Invasive monitoring (IM) and Stereo-electroencephalography (SEEG) for epilepsy surgery: nursing management Invasive monitoring (IM) and Stereo-electroencephalography (SEEG) for epilepsy surgery: nursing management (...) -disciplinary team especially the clinical physiologists and play specialist ( ). Obtain the child’s health record. Admit and clerk the child into the ward. Ascertain child’s infection status and complete admission infection screen. Ensure epilepsy specialist registrar and nurse practitioner (NP) examine the child and talk with the parent/carer(s) ( ). Ensure the child has observations taken and report abnormal observations using identified early warning score. Document in child’s the health care record

2014 Publication 1593